

# Global Kidney-Organ Chip Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G997741DA621EN.html>

Date: October 2026

Pages: 90

Price: US\$ 3,660.00 (Single User License)

ID: G997741DA621EN

## Abstracts

The global Kidney-Organ Chip market size is predicted to grow from US\$ 34.52 million in 2025 to US\$ 73.13 million in 2032; it is expected to grow at a CAGR of 10.9% from 2026 to 2032.

A Kidney-Organ Chip, more commonly described as a Kidney Organ-on-a-Chip, is a microengineered in vitro platform designed to reproduce selected structural, mechanical, and physiological characteristics of the human kidney. The system combines human renal cells with microfluidic channels, porous membranes, extracellular matrices, controlled perfusion, and biochemical stimulation to simulate kidney functions under dynamic conditions. Depending on the model design, it may replicate the glomerular filtration barrier, proximal-tubule secretion and reabsorption, distal-tubule transport, collecting-duct function, renal vasculature, or interactions among several nephron segments. Kidney-Organ Chips are primarily used in nephrotoxicity testing, renal disease modeling, drug transport and clearance studies, pharmacokinetic research, and development of personalized therapies. The market scope includes blank microfluidic chips, cell-loaded assay-ready models, kidney organoid-on-chip products, perfusion instruments, pumps, sensors, culture media, cells, software, analytical services, customized model development, training, and maintenance. These products are laboratory research and drug-development tools rather than implantable chips, dialysis systems, or therapeutic artificial kidneys.

## Key Findings

In 2025, global production of Kidney-Organ Chip was approximately 22,599 units.

Commercial models concentrate on proximal tubule and nephrotoxicity applications

Human cells and controlled perfusion improve renal physiological relevance

Drug developers and research institutions remain the primary customer groups

Assay-ready systems reduce operational barriers for pharmaceutical laboratories

Standardization and regulatory validation determine long-term market scalability

## Market Trends

Kidney-Organ Chip technology is progressing from basic single-channel cell-culture devices toward multicellular, vascularized, organoid-based, and interconnected renal models. Developers increasingly use human primary cells, immortalized renal cell lines, induced pluripotent stem-cell-derived cells, and adult stem-cell-derived organoids to improve physiological relevance. Dynamic perfusion and controlled shear stress support cell polarity, transporter expression, and long-term renal function. Another major trend is the development of standardized, microplate-compatible products that support automated liquid handling, high-content imaging, and medium- to high-throughput compound testing. Cell-loaded assay-ready models are becoming more important because they reduce model-establishment time and operator-dependent variability. Integrated sensors, real-time imaging, artificial-intelligence-assisted analysis, and transcriptomic or proteomic measurements are expanding functional readouts. Multi-organ configurations linking the kidney with the liver, intestine, heart, muscle, or immune system are also gaining attention for evaluating drug metabolism, systemic exposure, renal clearance, and inter-organ toxicity. These developments are gradually moving Kidney-Organ Chips from academic prototypes toward practical preclinical tools.

## Market Dynamics

Market development reflects the interaction between growing demand for human-relevant preclinical models and the technical difficulty of reproducing kidney physiology. Traditional animal models and static cell cultures may not fully represent human transporter expression, renal blood flow, tubular shear stress, metabolic activity, or species-specific drug responses. This limitation creates demand for dynamic human-cell-based models. Regulatory interest in new approach methodologies is encouraging pharmaceutical and biotechnology companies to assess microphysiological systems in safety and efficacy programs. However, commercial adoption remains selective because users must validate chip-generated results against conventional cell assays,

animal studies, clinical biomarkers, and historical compound data. Purchasing decisions therefore involve scientific collaboration, sample testing, protocol development, and internal qualification. Suppliers must demonstrate biological relevance as well as batch consistency, stable cell sourcing, practical operation, analytical reliability, and acceptable cost per experiment. Partnerships among platform developers, cell suppliers, pharmaceutical companies, contract research organizations, universities, and regulatory laboratories remain central to industry development.

## **Drivers**

The primary market driver is the need to detect drug-induced kidney injury earlier and more accurately during pharmaceutical development. Renal toxicity can result in program termination, clinical failure, restricted dosing, additional monitoring requirements, or post-market safety concerns. Conventional models may not reproduce the polarity, transporter activity, fluid flow, and epithelial-vascular interactions of the human kidney. Kidney-Organ Chips provide controlled environments for measuring drug exposure, secretion, reabsorption, permeability, biomarker release, and tissue injury over time. Growing research activity in acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, fibrosis, infection, and inherited renal disorders is also expanding demand for human disease models. Additional growth factors include advances in microfluidics, stem-cell differentiation, organoid culture, three-dimensional tissue engineering, and automated imaging. Policies promoting alternatives to animal testing and pharmaceutical investment in human-relevant models further support adoption. Together, these drivers are extending Kidney-Organ Chip use from academic research to mechanistic toxicology, compound screening, translational studies, and preclinical decision support.

## **Restraints**

Commercial expansion is restrained by the biological complexity of the kidney and the lack of universally accepted validation standards. The kidney contains multiple nephron segments, specialized epithelial cells, endothelial cells, stromal cells, immune components, and complex vascular structures responsible for filtration, secretion, reabsorption, concentration, and endocrine regulation. Most commercial models reproduce only selected functions rather than the complete organ. Human primary renal cells may exhibit donor variability and limited expansion, while immortalized or stem-cell-derived cells may not fully achieve adult tissue maturity. Microfluidic systems may experience bubbles, evaporation, contamination, inconsistent flow, material absorption, and operational complexity. Customers can also require specialized pumps, imaging equipment, analytical methods, and trained personnel. Differences in chip geometry,

cell type, extracellular matrix, medium, flow rate, exposure protocol, and endpoint selection reduce comparability between platforms. Until reference compounds, performance criteria, interlaboratory studies, and regulatory pathways become more established, Kidney-Organ Chips will mainly complement rather than completely replace existing preclinical methods.

## Opportunities

The strongest commercial opportunities lie in standardized and assay-ready Kidney-Organ Chip models that provide reproducible results with limited user preparation. Pharmaceutical companies require scalable platforms for nephrotoxicity screening, renal transporter analysis, biomarker assessment, compound prioritization, and mechanism-of-injury studies. Disease-specific models constructed from patient-derived cells or induced pluripotent stem cells offer opportunities in rare kidney diseases, inherited disorders, precision medicine, and individualized therapeutic development. Multi-organ systems connecting the kidney with the liver, intestine, muscle, heart, or immune system can support pharmacokinetic, metabolism, systemic toxicity, and organ-interaction studies. Suppliers can also expand through customized model development, contract testing, data analysis, regulatory consulting, software, training, and cell-and-reagent packages. Compatibility with automated laboratory workflows and standard microplate formats could accelerate adoption by large pharmaceutical organizations. China, Japan, and South Korea offer additional opportunities through expanding biopharmaceutical research, microfluidic manufacturing capabilities, organoid programs, and policies supporting alternatives to animal testing. Partnerships with contract research organizations and cell suppliers can further strengthen market access.

## Challenges

The principal challenge is generating biologically meaningful and repeatable data suitable for pharmaceutical and regulatory decisions. Renal cells must maintain appropriate polarity, transporter expression, barrier integrity, metabolic activity, and responses to physiological flow throughout the required culture period. Variations in cell source, extracellular matrix, medium composition, chip material, flow conditions, and dosing procedures can materially affect results. Developers must also establish clinically relevant endpoints, including transport activity, permeability, morphology, gene expression, tissue-injury biomarkers, and recovery responses. Scaling from laboratory prototypes to standardized commercial products requires consistent microfabrication, membrane quality, surface treatment, sterilization, cell loading, packaging, storage, and shipment. Another challenge is balancing physiological complexity with throughput and operational simplicity. Highly complex vascularized or multi-organ models may offer

stronger biological relevance but can be more difficult and expensive to operate. Wider adoption will require reference-compound testing, transparent performance benchmarks, standardized data formats, interlaboratory validation, and clearer regulatory acceptance of Kidney-Organ Chip evidence.

## Industry Chain Analysis

The upstream industry includes microfluidic polymers, glass substrates, porous membranes, extracellular matrices, surface coatings, renal cells, stem cells, organoids, culture media, growth factors, pumps, valves, tubing, sensors, imaging systems, and laboratory automation equipment. The quality of these inputs directly influences cell viability, flow stability, optical performance, compound absorption, and experimental reproducibility. Midstream companies design and manufacture microfluidic chips, integrate perfusion equipment, construct renal tissue models, optimize culture protocols, develop analytical software, validate biological functions, and provide assay-ready products or customized testing services. Their competitiveness depends on combining microengineering, cell biology, tissue engineering, pharmacology, and data analysis. Downstream customers include pharmaceutical and biotechnology companies, contract research organizations, universities, hospitals, government laboratories, chemical companies, cosmetics companies, and regulatory research institutions. Products reach customers through direct technical sales, specialized scientific distributors, collaborative development agreements, and contract-service models. Installation, training, model development, data interpretation, software support, and consumable supply constitute an important service layer.

## Value Chain Analysis

The physical chip is only one part of the Kidney-Organ Chip value chain. Greater value is created through qualified cell sourcing, biological model establishment, extracellular-matrix optimization, fluidic control, functional validation, analytical endpoints, software, and translational interpretation. Empty chips and general-purpose perfusion equipment provide flexibility but require users to possess advanced cell-culture and microfluidic expertise. Cell-loaded assay-ready models provide greater practical value by reducing model-development time, minimizing operator variability, and enabling customers to focus on compound testing. Customized services further enhance value by adapting models to specific renal diseases, drug mechanisms, biomarkers, or regulatory questions. Data analysis and application support become increasingly important when users need to correlate chip results with animal studies, clinical biomarkers, pharmacokinetic models, and internal decision systems. Recurring revenue can be

generated from disposable chips, cells, media, reagents, software, maintenance, calibration, training, and contract assays. Companies integrating engineering capabilities with validated biological models are better positioned to capture value across the product lifecycle.

## Segment Insights

By simulated renal structure, Kidney-Organ Chips can be divided into glomerulus-on-chip, proximal-tubule-on-chip, distal-tubule or collecting-duct models, and integrated nephron or multi-organ systems. Proximal-tubule models represent the most commercially developed segment because they support nephrotoxicity, secretion, reabsorption, and transporter studies. By technical architecture, the market includes membrane-based dual-channel devices, three-dimensional matrix-embedded tubular models, organoid-on-chip platforms, vascularized renal models, and bioprinted chips. By product form, products can be classified into blank chips and consumables, cell-loaded assay-ready models, perfusion instruments and complete systems, and customized testing services. By cell source, models use primary human renal cells, immortalized cell lines, induced pluripotent stem-cell-derived cells, or adult stem-cell-derived organoids. Major applications include drug-induced nephrotoxicity testing, renal disease modeling, drug transport and clearance studies, pharmacokinetic and ADME analysis, and personalized medicine. Selection depends on biological complexity, throughput, repeatability, operating difficulty, and required analytical endpoints.

## Downstream Market Opportunities

Drug-induced nephrotoxicity testing represents the leading downstream opportunity because pharmaceutical developers need to identify compounds that damage glomerular, tubular, vascular, or interstitial tissues before clinical trials. Kidney-Organ Chips can support dose-response analysis, compound ranking, transporter studies, biomarker evaluation, and investigation of injury mechanisms. Renal disease modeling offers opportunities in acute kidney injury, chronic kidney disease, diabetic nephropathy, polycystic kidney disease, fibrosis, infection, and inherited disorders. Drug-transport and clearance models can improve understanding of secretion, reabsorption, metabolite handling, and drug-drug interactions. Multi-organ systems enable analysis of metabolites generated by the liver, substances absorbed through the intestine, and systemic toxicity involving the kidney and other tissues. Patient-derived cells and kidney organoids create longer-term opportunities in precision medicine and individualized therapy selection. Pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions are the primary customers, while chemical,

cosmetics, food, and environmental-safety organizations represent additional demand for renal toxicity assessment.

## Regional Insights

North America is an important center for Kidney-Organ Chip commercialization, pharmaceutical adoption, academic research, and regulatory collaboration, supported by companies such as Emulate, Nortis, Hesperos, and Creative Biolabs. Europe has also established a strong position in organ-on-a-chip platforms, with MIMETAS, TissUse, CN Bio, Kirkstall, BEOnChip, InSphero, and Fluigent participating in kidney models, multi-organ systems, perfusion equipment, or enabling technologies. The region benefits from established pharmaceutical research, microfluidics expertise, and policies supporting non-animal testing. Asia-Pacific is developing rapidly as China, Japan, and South Korea increase investment in organoid technologies, microphysiological systems, drug-safety evaluation, and domestic laboratory equipment. Beijing Daxiang Biotech is active in organoid-chip models in China, while Nanosystems Japan and EDmicBio participate in microfluidic fabrication and three-dimensional organ-chip development. Regional expansion will depend on pharmaceutical partnerships, local cell resources, technical-service networks, regulatory validation, and the availability of trained users.

## Competitive Landscape Analysis

The competitive landscape includes dedicated Kidney-Organ Chip suppliers, broader organ-on-a-chip platform companies, perfusion-system manufacturers, microfluidic-device producers, and contract model-development providers. Emulate offers a validated Kidney-Chip model, while MIMETAS provides perfused kidney models and kidney organoid tubules through its OrganoPlate platform. Nortis is recognized for proximal-tubule chips, and TissUse develops kidney-containing multi-organ systems. CN Bio and Hesperos provide platforms capable of incorporating kidney tissues into single- or multi-organ studies. Creative Biolabs offers customized Kidney-Organ Chip development, while Kirkstall, BEOnChip, InSphero, Fluigent, and Microfluidics Innovation Center provide adaptable organ-chip, perfusion, or renal-model solutions. Asian participants include Beijing Daxiang Biotech, Nanosystems Japan, and EDmicBio. Competitive differentiation centers on renal physiological relevance, validated function, reproducibility, throughput, ease of use, cell quality, automation, data analysis, application support, and regulatory credibility rather than on microfluidic-chip production capacity alone.

## Report Scope

LPI (LP Information)' newest research report, the “Kidney-Organ Chip Industry Forecast” looks at past sales and reviews total world Kidney-Organ Chip sales in 2025, providing a comprehensive analysis by region and market sector of projected Kidney-Organ Chip sales for 2026 through 2032. With Kidney-Organ Chip sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Kidney-Organ Chip industry.

This Insight Report provides a comprehensive analysis of the global Kidney-Organ Chip landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Kidney-Organ Chip portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Kidney-Organ Chip market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney-Organ Chip and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney-Organ Chip.

This report presents a comprehensive overview, market shares, and growth opportunities of Kidney-Organ Chip market by product type, application, key players and key regions and countries.

## Market Segmentation

### Segmentation by Type:

Glomerular Chip

Renal Tubule Chip

Colliding Duct Chip

## **Segmentation by Structure:**

Membrane-Based Dual-Channel Type

3D Matrix-Embedded Tubular Type

## **Segmentation by Source:**

Primary Human Cell-Based Type

Immortalized Cell Line-Based Type

Stem Cell & Organoid-Based Type

## **Segmentation by Application:**

Hospitals

Research Institutions

Universities

Others

## **This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

## APAC

China

Japan

Korea

Southeast Asia

India

Australia

## Europe

Germany

France

UK

Italy

Russia

## Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Emulate

Mimetas

TissUse

Valo Health

CN Bio Innovations

Draper Laboratory

Nortis

Xona Microfluidics

SynVivo

Beijing Daxiang Biotech

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Kidney-Organ Chip Market Size 2026-2032
  - 2.1.2 Kidney-Organ Chip Market Size CAGR by Region
- 2.2 Kidney-Organ Chip Segment by Type
  - 2.2.1 Glomerular Chip
  - 2.2.2 Renal Tubule Chip
  - 2.2.3 Colliding Duct Chip
  - 2.2.4 Kidney-Organ Chip Market Size by Type
    - 2.2.4.1 Global Kidney-Organ Chip Market Size Market Share by Type (2026-2032)
    - 2.2.4.2 Global Kidney-Organ Chip Market Size Growth Rate by Type (2026-2032)
- 2.3 Kidney-Organ Chip Segment by Structure
  - 2.3.1 Membrane-Based Dual-Channel Type
  - 2.3.2 3D Matrix-Embedded Tubular Type
  - 2.3.3 Kidney-Organ Chip Market Size by Structure
    - 2.3.3.1 Global Kidney-Organ Chip Market Size Market Share by Structure (2026-2032)
    - 2.3.3.2 Global Kidney-Organ Chip Market Size Growth Rate by Structure (2026-2032)
- 2.4 Kidney-Organ Chip Segment by Source
  - 2.4.1 Primary Human Cell-Based Type
  - 2.4.2 Immortalized Cell Line-Based Type
  - 2.4.3 Stem Cell & Organoid-Based Type
  - 2.4.4 Kidney-Organ Chip Market Size by Source
    - 2.4.4.1 Global Kidney-Organ Chip Market Size Market Share by Source (2026-2032)
    - 2.4.4.2 Global Kidney-Organ Chip Market Size Growth Rate by Source (2026-2032)
- 2.5 Kidney-Organ Chip Segment by Application

2.5.1 Hospitals

2.5.2 Research Institutions

2.5.3 Universities

2.5.4 Others

2.5.5 Kidney-Organ Chip Market Size by Application (2026-2032)

2.5.5.1 Global Kidney-Organ Chip Market Size Market Share by Application (2026-2032)

2.5.5.2 Global Kidney-Organ Chip Market Size Growth Rate by Application (2026-2032)

### **3 KIDNEY-ORGAN CHIP KEY PLAYERS**

3.1 Date of Key Players Enter into Kidney-Organ Chip

3.2 Key Players Kidney-Organ Chip Product Offered

3.3 Key Players Kidney-Organ Chip Funding/Investment Analysis

3.4 Funding/Investment

3.4.1 Funding/Investment by Regions

3.4.2 Funding/Investment by End-Industry

3.5 Key Players Kidney-Organ Chip Valuation & Market Capitalization

3.6 Key Players Mergers & Acquisitions, Expansion Plans

3.7 Market Ranking

3.8 New Product/Technology Launches

3.9 Partnerships, Agreements, and Collaborations

3.10 Mergers and Acquisitions

### **4 KIDNEY-ORGAN CHIP BY REGIONS**

4.1 Kidney-Organ Chip Market Size by Regions (2026-2032)

4.2 United States Kidney-Organ Chip Market Size Growth (2026-2032)

4.3 China Kidney-Organ Chip Market Size Growth (2026-2032)

4.4 Europe Kidney-Organ Chip Market Size Growth (2026-2032)

4.5 Rest of World Kidney-Organ Chip Market Size Growth (2026-2032)

### **5 UNITED STATES**

5.1 United States Kidney-Organ Chip Market Size by Type (2026-2032)

5.2 United States Kidney-Organ Chip Market Size by Application (2026-2032)

### **6 EUROPE**

6.1 Europe Kidney-Organ Chip Market Size by Type (2026-2032)

6.2 Europe Kidney-Organ Chip Market Size by Application (2026-2032)

## **7 CHINA**

7.1 China Kidney-Organ Chip Market Size by Type (2026-2032)

7.2 China Kidney-Organ Chip Market Size by Application (2026-2032)

## **8 REST OF WORLD**

8.1 Rest of World Kidney-Organ Chip Market Size by Type (2026-2032)

8.2 Rest of World Kidney-Organ Chip Market Size by Application (2026-2032)

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 KEY INVESTORS IN KIDNEY-ORGAN CHIP**

10.1 Company A

10.1.1 Company A Company Details

10.1.2 Company Description

10.1.3 Companies Invested by Company A

10.1.4 Company A Key Development and Market Layout

10.2 Company B

10.2.1 Company B Company Details

10.2.2 Company Description

10.2.3 Companies Invested by Company B

10.2.4 Company B Key Development and Market Layout

10.3 Company C

10.3.1 Company C Company Details

10.3.2 Company Description

10.3.3 Companies Invested by Company C

- 10.3.4 Company C Key Development and Market Layout
- 10.4 Company D
- 10.5 .....

## **11 KEY PLAYERS ANALYSIS**

### **11.1 Emulate**

- 11.1.1 Emulate Company Details
- 11.1.2 Emulate Kidney-Organ Chip Product Offered
- 11.1.3 Emulate Kidney-Organ Chip Market Size (2025 VS 2031)
- 11.1.4 Emulate Main Business Overview
- 11.1.5 Emulate News

### **11.2 Mimetas**

- 11.2.1 Mimetas Company Details
- 11.2.2 Mimetas Kidney-Organ Chip Product Offered
- 11.2.3 Mimetas Kidney-Organ Chip Market Size (2025 VS 2031)
- 11.2.4 Mimetas Main Business Overview
- 11.2.5 Mimetas News

### **11.3 TissUse**

- 11.3.1 TissUse Company Details
- 11.3.2 TissUse Kidney-Organ Chip Product Offered
- 11.3.3 TissUse Kidney-Organ Chip Market Size (2025 VS 2031)
- 11.3.4 TissUse Main Business Overview
- 11.3.5 TissUse News

### **11.4 Valo Health**

- 11.4.1 Valo Health Company Details
- 11.4.2 Valo Health Kidney-Organ Chip Product Offered
- 11.4.3 Valo Health Kidney-Organ Chip Market Size (2025 VS 2031)
- 11.4.4 Valo Health Main Business Overview
- 11.4.5 Valo Health News

### **11.5 CN Bio Innovations**

- 11.5.1 CN Bio Innovations Company Details
- 11.5.2 CN Bio Innovations Kidney-Organ Chip Product Offered
- 11.5.3 CN Bio Innovations Kidney-Organ Chip Market Size (2025 VS 2031)
- 11.5.4 CN Bio Innovations Main Business Overview
- 11.5.5 CN Bio Innovations News

### **11.6 Draper Laboratory**

- 11.6.1 Draper Laboratory Company Details
- 11.6.2 Draper Laboratory Kidney-Organ Chip Product Offered

11.6.3 Draper Laboratory Kidney-Organ Chip Market Size (2025 VS 2031)

11.6.4 Draper Laboratory Main Business Overview

11.6.5 Draper Laboratory News

11.7 Nortis

11.7.1 Nortis Company Details

11.7.2 Nortis Kidney-Organ Chip Product Offered

11.7.3 Nortis Kidney-Organ Chip Market Size (2025 VS 2031)

11.7.4 Nortis Main Business Overview

11.7.5 Nortis News

11.8 Xona Microfluidics

11.8.1 Xona Microfluidics Company Details

11.8.2 Xona Microfluidics Kidney-Organ Chip Product Offered

11.8.3 Xona Microfluidics Kidney-Organ Chip Market Size (2025 VS 2031)

11.8.4 Xona Microfluidics Main Business Overview

11.8.5 Xona Microfluidics News

11.9 SynVivo

11.9.1 SynVivo Company Details

11.9.2 SynVivo Kidney-Organ Chip Product Offered

11.9.3 SynVivo Kidney-Organ Chip Market Size (2025 VS 2031)

11.9.4 SynVivo Main Business Overview

11.9.5 SynVivo News

11.10 Beijing Daxiang Biotech

11.10.1 Beijing Daxiang Biotech Company Details

11.10.2 Beijing Daxiang Biotech Kidney-Organ Chip Product Offered

11.10.3 Beijing Daxiang Biotech Kidney-Organ Chip Market Size (2025 VS 2031)

11.10.4 Beijing Daxiang Biotech Main Business Overview

11.10.5 Beijing Daxiang Biotech News

## **12 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. Kidney-Organ Chip Market Size CAGR by Region (2026-2032) (\$ millions)
- Table 2. Major Players of Glomerular Chip
- Table 3. Major Players of Renal Tubule Chip
- Table 4. Major Players of Colliding Duct Chip
- Table 5. Global Market Size by Type (2026-2032) (\$ millions)
- Table 6. Global Kidney-Organ Chip Market Size Market Share by Type (2026-2032)
- Table 7. Major Players of Membrane-Based Dual-Channel Type
- Table 8. Major Players of 3D Matrix-Embedded Tubular Type
- Table 9. Global Market Size by Structure (2026-2032) (\$ millions)
- Table 10. Global Kidney-Organ Chip Market Size Market Share by Structure (2026-2032)
- Table 11. Major Players of Primary Human Cell-Based Type
- Table 12. Major Players of Immortalized Cell Line-Based Type
- Table 13. Major Players of Stem Cell & Organoid-Based Type
- Table 14. Global Market Size by Source (2026-2032) (\$ millions)
- Table 15. Global Kidney-Organ Chip Market Size Market Share by Source (2026-2032)
- Table 16. Global Kidney-Organ Chip Market Size by Application (2026-2032) (\$ millions)
- Table 17. Global Kidney-Organ Chip Market Size Market Share by Application (2026-2032)
- Table 18. Date of Global Key Players Enter into Kidney-Organ Chip Market
- Table 19. Global Key Players Kidney-Organ Chip Product Offered
- Table 20. Key Players Kidney-Organ Chip Funding/Investment (Million USD)
- Table 21. Funding/Investment by Regions
- Table 22. Funding/Investment by End-Industry
- Table 23. Key Players Kidney-Organ Chip Valuation & Market Capitalization (Million USD)
- Table 24. Key Players Mergers & Acquisitions, Expansion Plans
- Table 25. Kidney-Organ Chip New Product/Technology Launches
- Table 26. Kidney-Organ Chip Industry Partnerships, Agreements, and Collaborations
- Table 27. Kidney-Organ Chip Industry Mergers and Acquisitions
- Table 28. Global Kidney-Organ Chip Market Size by Regions 2026-2032 (\$ millions)
- Table 29. Global Kidney-Organ Chip Market Size Market Share by Regions 2026-2032
- Table 30. United States Kidney-Organ Chip Market Size by Type (2026-2032) (\$ millions)

Table 31. United States Kidney-Organ Chip Market Size Market Share by Type (2026-2032)

Table 32. United States Kidney-Organ Chip Market Size by Application (2026-2032) (\$ millions)

Table 33. United States Kidney-Organ Chip Market Size Market Share by Application (2026-2032)

Table 34. Europe Kidney-Organ Chip Market Size by Type (2026-2032) (\$ millions)

Table 35. Europe Kidney-Organ Chip Market Size Market Share by Type (2026-2032)

Table 36. Europe Kidney-Organ Chip Market Size by Application (2026-2032) (\$ millions)

Table 37. Europe Kidney-Organ Chip Market Size Market Share by Application (2026-2032)

Table 38. China Kidney-Organ Chip Market Size by Type (2026-2032) (\$ millions)

Table 39. China Kidney-Organ Chip Market Size Market Share by Type (2026-2032)

Table 40. China Kidney-Organ Chip Market Size by Application (2026-2032) (\$ millions)

Table 41. China Kidney-Organ Chip Market Size Market Share by Application (2026-2032)

Table 42. Rest of World Kidney-Organ Chip Market Size by Type (2026-2032) (\$ millions)

Table 43. Rest of World Kidney-Organ Chip Market Size Market Share by Type (2026-2032)

Table 44. Rest of World Kidney-Organ Chip Market Size by Application (2026-2032) (\$ millions)

Table 45. Rest of World Kidney-Organ Chip Market Size Market Share by Application (2026-2032)

Table 46. Key Market Drivers & Growth Opportunities of Kidney-Organ Chip

Table 47. Key Market Challenges & Risks of Kidney-Organ Chip

Table 48. Key Industry Trends of Kidney-Organ Chip

Table 49. Company A Company Details

Table 50. Companies Invested by Company A

Table 51. Company A Key Development and Market Layout

Table 52. Company B Company Details

Table 53. Companies Invested by Company B

Table 54. Company B Key Development and Market Layout

Table 55. Company C Company Details

Table 56. Companies Invested by Company C

Table 57. Company C Key Development and Market Layout

Table 58. Emulate Basic Information, Head Office, Major Market Areas and Its Competitors

Table 59. Emulate Kidney-Organ Chip Market Size (2025 VS 2031)

Table 60. Mimetas Basic Information, Head Office, Major Market Areas and Its Competitors

Table 61. Mimetas Kidney-Organ Chip Market Size (2025 VS 2031)

Table 62. TissUse Basic Information, Head Office, Major Market Areas and Its Competitors

Table 63. TissUse Kidney-Organ Chip Market Size (2025 VS 2031)

Table 64. Valo Health Basic Information, Head Office, Major Market Areas and Its Competitors

Table 65. Valo Health Kidney-Organ Chip Market Size (2025 VS 2031)

Table 66. CN Bio Innovations Basic Information, Head Office, Major Market Areas and Its Competitors

Table 67. CN Bio Innovations Kidney-Organ Chip Market Size (2025 VS 2031)

Table 68. Draper Laboratory Basic Information, Head Office, Major Market Areas and Its Competitors

Table 69. Draper Laboratory Kidney-Organ Chip Market Size (2025 VS 2031)

Table 70. Nortis Basic Information, Head Office, Major Market Areas and Its Competitors

Table 71. Nortis Kidney-Organ Chip Market Size (2025 VS 2031)

Table 72. Xona Microfluidics Basic Information, Head Office, Major Market Areas and Its Competitors

Table 73. Xona Microfluidics Kidney-Organ Chip Market Size (2025 VS 2031)

Table 74. SynVivo Basic Information, Head Office, Major Market Areas and Its Competitors

Table 75. SynVivo Kidney-Organ Chip Market Size (2025 VS 2031)

Table 76. Beijing Daxiang Biotech Basic Information, Head Office, Major Market Areas and Its Competitors

Table 77. Beijing Daxiang Biotech Kidney-Organ Chip Market Size (2025 VS 2031)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Kidney-Organ Chip
- Figure 2. Kidney-Organ Chip Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Kidney-Organ Chip Market Size Growth Rate 2026-2032 (\$ millions)
- Figure 7. Kidney-Organ Chip Market Size by Region (2025 & 2032) (\$ millions)
- Figure 8. Global Kidney-Organ Chip Market Size Market Share by Type (2026-2032)
- Figure 9. Global Glomerular Chip Market Size Growth Rate
- Figure 10. Global Renal Tubule Chip Market Size Growth Rate
- Figure 11. Global Kidney-Organ Chip Market Size Market Share by Structure (2026-2032)
- Figure 12. Global Membrane-Based Dual-Channel Type Market Size Growth Rate
- Figure 13. Global 3D Matrix-Embedded Tubular Type Market Size Growth Rate
- Figure 14. Global Kidney-Organ Chip Market Size Market Share by Source (2026-2032)
- Figure 15. Global Primary Human Cell-Based Type Market Size Growth Rate
- Figure 16. Global Immortalized Cell Line-Based Type Market Size Growth Rate
- Figure 17. Kidney-Organ Chip in Hospitals
- Figure 18. Global Kidney-Organ Chip Market: Hospitals (2026-2032) (\$ millions)
- Figure 19. Kidney-Organ Chip in Research Institutions
- Figure 20. Global Kidney-Organ Chip Market: Research Institutions (2026-2032) (\$ millions)
- Figure 21. Kidney-Organ Chip in Universities
- Figure 22. Global Kidney-Organ Chip Market: Universities (2026-2032) (\$ millions)
- Figure 23. Kidney-Organ Chip in Others
- Figure 24. Global Kidney-Organ Chip Market: Others (2026-2032) (\$ millions)
- Figure 25. Global Kidney-Organ Chip Market Size Market Share by Application (2026-2032)
- Figure 26. Global Kidney-Organ Chip Market Size in Hospitals Growth Rate
- Figure 27. Global Kidney-Organ Chip Market Size in Research Institutions Growth Rate
- Figure 28. Funding/Investment
- Figure 29. Global Kidney-Organ Chip Market Size Market Share by Regions 2026-2032
- Figure 30. United States Kidney-Organ Chip Market Size 2026-2032 (\$ millions)
- Figure 31. China Kidney-Organ Chip Market Size 2026-2032 (\$ millions)
- Figure 32. Europe Kidney-Organ Chip Market Size 2026-2032 (\$ millions)

Figure 33. Rest of World Kidney-Organ Chip Market Size 2026-2032 (\$ millions)

Figure 34. United States Kidney-Organ Chip Consumption Market Share by Type in 2030

Figure 35. United States Kidney-Organ Chip Market Size Market Share by Application in 2030

Figure 36. Europe Kidney-Organ Chip Consumption Market Share by Type in 2030

Figure 37. Europe Kidney-Organ Chip Market Size Market Share by Application in 2030

Figure 38. China Kidney-Organ Chip Consumption Market Share by Type in 2030

Figure 39. China Kidney-Organ Chip Market Size Market Share by Application in 2030

Figure 40. Rest of World Kidney-Organ Chip Consumption Market Share by Type in 2030

Figure 41. Rest of World Kidney-Organ Chip Market Size Market Share by Application in 2030

## I would like to order

Product name: Global Kidney-Organ Chip Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G997741DA621EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G997741DA621EN.html>